NOB1P Inhibitors
Chemical inhibitors of NOB1P include a range of proteasome inhibitors that disrupt the protein's functional state by impeding the degradation process that is essential for protein turnover and cellular regulation. Bortezomib, MG-132, and Lactacystin, for example, all function by binding to the proteasomal subunits to prevent the breakdown of ubiquitinated proteins. This action can lead to an accumulation of these proteins within the cell, including potentially misfolded or dysfunctional NOB1P, which as a result, may become functionally inactive. Similarly, Velcade, a synonym for Bortezomib, exerts its inhibitory effect by binding to the 26S proteasome complex, causing an accumulation of ubiquitinated proteins, including NOB1P, potentially leading to its functional inhibition. Carfilzomib and Oprozomib, both selective proteasome inhibitors, irreversibly bind to the proteasome, which could result in the accumulation of NOB1P and subsequent hampering of its function. Marizomib extends this list by being another powerful proteasome inhibitor, potentially leading to a blockade of NOB1P degradation.
Continuing with the theme of proteasome inhibition, Epoxomicin, Ixazomib, and Delanzomib also contribute to the inhibition of NOB1P by targeting the proteasome's active sites, thereby interfering with the degradation of protein substrates, such as NOB1P. This interference can lead to the stabilization of NOB1P in an inactive form. Auranofin, while not a proteasome inhibitor, disrupts cellular redox balance by inhibiting thioredoxin reductase. This disruption can impair the proper folding and function of various proteins, which can include NOB1P, leading to its inhibition. Lastly, Eeyarestatin I, by inhibiting the ER-associated degradation pathway, can prevent the proper disposal of misfolded NOB1P proteins, causing an inhibition of their function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can indirectly inhibit NOB1P by preventing the degradation of ubiquitinated proteins, thereby potentially causing a buildup of proteins that may include misfolded or improperly formed NOB1P, leading to its functional inactivity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 functions similarly to Bortezomib by inhibiting the proteasome, which may lead to an accumulation of polyubiquitinated NOB1P, thus hindering its proper function. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is another proteasome inhibitor that can cause an accumulation of proteins within the cell, including NOB1P. This accumulation can disrupt the normal turnover and function of NOB1P. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is a selective proteasome inhibitor that irreversibly binds to the proteasome, potentially causing the functional inhibition of NOB1P by preventing its normal degradation and processing. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib, an oral proteasome inhibitor, could inhibit NOB1P by disrupting the normal proteasome-mediated turnover of proteins, potentially affecting NOB1P's function. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor that could inhibit NOB1P by blocking the degradation of proteasome substrates, potentially affecting the stability and function of NOB1P. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib is a proteasome inhibitor that could lead to the functional inhibition of NOB1P by disrupting the normal degradation pathway of the proteasome, which may include the turnover of NOB1P. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib is a proteasome inhibitor that can inhibit NOB1P function by preventing the proteasomal degradation of proteins, potentially leading to the accumulation of non-functional NOB1P. | ||||||
Auranofin | 34031-32-8 | sc-202476 sc-202476A sc-202476B | 25 mg 100 mg 2 g | $153.00 $214.00 $4000.00 | 39 | |
Auranofin is a thioredoxin reductase inhibitor that can disrupt the cellular redox balance, which is necessary for the proper folding and function of many proteins, possibly including NOB1P. | ||||||
Eeyarestatin I | 412960-54-4 | sc-358130B sc-358130 sc-358130A sc-358130C sc-358130D sc-358130E | 5 mg 10 mg 25 mg 50 mg 100 mg 500 mg | $114.00 $203.00 $354.00 $697.00 $1363.00 $5836.00 | 12 | |
Eeyarestatin I is an inhibitor of the ER-associated degradation (ERAD) pathway which could lead to the functional inhibition of NOB1P by impairing the degradation of misfolded NOB1P proteins in the ER. | ||||||